RS105304A - Methods of treating angiogenesis,tumor growth,and metastasis - Google Patents
Methods of treating angiogenesis,tumor growth,and metastasisInfo
- Publication number
- RS105304A RS105304A YUP-1053/04A YUP105304A RS105304A RS 105304 A RS105304 A RS 105304A YU P105304 A YUP105304 A YU P105304A RS 105304 A RS105304 A RS 105304A
- Authority
- RS
- Serbia
- Prior art keywords
- metastasis
- methods
- tumor growth
- treating angiogenesis
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Predmetni pronalazak se odnosi na postupak za lečenje kancera ili neželjene angiogeneze kod pacijenta, koji obuhvata primenu na pacijentu farmaceutskog preparata koji sadrži ugljen monoksid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38656102P | 2002-06-05 | 2002-06-05 | |
PCT/US2003/017731 WO2003103585A2 (en) | 2002-06-05 | 2003-06-05 | Methods of treating angiogenesis, tumor growth, and metastasis |
Publications (1)
Publication Number | Publication Date |
---|---|
RS105304A true RS105304A (en) | 2007-02-05 |
Family
ID=29736179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YUP-1053/04A RS105304A (en) | 2002-06-05 | 2003-06-05 | Methods of treating angiogenesis,tumor growth,and metastasis |
Country Status (14)
Country | Link |
---|---|
US (1) | US20040258772A1 (sr) |
EP (1) | EP1509237A4 (sr) |
JP (1) | JP2005532351A (sr) |
CN (1) | CN1674922A (sr) |
AU (1) | AU2003248621A1 (sr) |
CA (1) | CA2487413A1 (sr) |
EA (1) | EA200401622A1 (sr) |
HR (1) | HRP20041146A2 (sr) |
MX (1) | MXPA04012167A (sr) |
NO (1) | NO20045354L (sr) |
PL (1) | PL374375A1 (sr) |
RS (1) | RS105304A (sr) |
UA (1) | UA87438C2 (sr) |
WO (1) | WO2003103585A2 (sr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7678390B2 (en) | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
GB0111872D0 (en) | 2001-05-15 | 2001-07-04 | Northwick Park Inst For Medica | Therapeutic agents and methods |
WO2003000114A2 (en) * | 2001-06-21 | 2003-01-03 | Beth Israel Deaconess Medical Center | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis |
US20080026984A1 (en) * | 2002-02-04 | 2008-01-31 | Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof |
US7968605B2 (en) * | 2002-02-04 | 2011-06-28 | ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof |
CA2475209A1 (en) | 2002-02-04 | 2003-08-14 | Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda. | Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
MXPA04010243A (es) | 2002-04-15 | 2005-07-05 | Univ Pittsburgh | Metodos para tratar ileo. |
JP2005522521A (ja) | 2002-04-15 | 2005-07-28 | ベス イスラエル デアコネス メディカル センター | ヘムオキシゲナーゼ−1およびヘム分解産物の使用法 |
UA86570C2 (ru) * | 2002-04-15 | 2009-05-12 | Юниверсити Оф Питтсбург Оф Дзе Коммонвелз Систем Оф Хайер Эдьюкейшн | Способ лечения некротизирующего энтероколита |
US20040052866A1 (en) | 2002-05-17 | 2004-03-18 | Otterbein Leo E. | Methods of treating hepatitis |
AU2003279236B8 (en) * | 2002-06-21 | 2009-02-19 | Beth Israel Deaconess Medical Center, Inc. | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
DE10230165A1 (de) * | 2002-07-04 | 2004-01-15 | Ino Therapeutics Gmbh | Verfahren und Vorrichtung zur Administration von Kohlenmonoxid |
US20100158795A1 (en) * | 2008-06-12 | 2010-06-24 | Pulmonx | Methods and systems for assessing lung function and delivering therapeutic agents |
EA200500782A1 (ru) * | 2002-11-07 | 2005-10-27 | Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн | Лечение геморрагического шока |
GB2395432B (en) * | 2002-11-20 | 2005-09-14 | Northwick Park Inst For Medica | Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs |
AU2004262976A1 (en) * | 2003-08-04 | 2005-02-17 | Hemocorm Limited | Use of boranocarbonates for the therapeutic delivery of carbon monoxide |
CN100475275C (zh) * | 2004-01-05 | 2009-04-08 | 董永华 | 肿瘤血管栓塞剂及其储存和释放装置 |
WO2007073226A1 (en) * | 2005-12-20 | 2007-06-28 | Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda | Method for treating a mammal by administration of a compound having the ability to release co |
JPWO2007073005A1 (ja) * | 2005-12-22 | 2009-06-04 | 学校法人慶應義塾 | メチル基転移反応調節物質 |
GB0601394D0 (en) | 2006-01-24 | 2006-03-01 | Hemocorm Ltd | Therapeutic delivery of carbon monoxide |
JP5552262B2 (ja) * | 2009-05-13 | 2014-07-16 | フクダ電子株式会社 | 肺疾患の治療に用いられる気体製剤 |
US9980981B2 (en) | 2011-01-14 | 2018-05-29 | Children's Hospital Los Angeles | Solution of carbon monoxide for the treatment of disease, including sickle cell disease |
WO2012145520A2 (en) | 2011-04-19 | 2012-10-26 | Alfama, Inc. | Carbon monoxide releasing molecules and uses thereof |
JP6134710B2 (ja) | 2011-07-21 | 2017-05-24 | アルファーマ インコーポレイテッドAlfama,Inc. | 一酸化ルテニウム放出分子およびその使用 |
CA2844660A1 (en) * | 2011-08-09 | 2013-02-14 | Leo E. Otterbein | Methods of treating dna damage |
WO2018225785A1 (ja) * | 2017-06-06 | 2018-12-13 | 株式会社Atomis | ワクチン組成物 |
EP4065133A4 (en) | 2019-11-25 | 2024-05-22 | Beyond Air, Inc. | METHOD USING GASEOUS NITROGEN MONOXIDE TO INHIBIT TUMOR GROWTH |
WO2022015986A1 (en) * | 2020-07-16 | 2022-01-20 | Cornell University | Methods for treating metastatic cancer using low dose carbon monoxide |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4053590A (en) * | 1975-02-27 | 1977-10-11 | Alza Corporation | Compositions of matter comprising macromolecular hemoglobin |
US4264739A (en) * | 1979-01-05 | 1981-04-28 | Merck & Co., Inc. | Sparger for cell culture system |
US5240912A (en) * | 1983-05-09 | 1993-08-31 | Todaro George J | Transforming growth factor (TGF) peptides |
US5084380A (en) * | 1985-01-29 | 1992-01-28 | Applied Biotechnology | Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins |
US5449665A (en) * | 1985-09-24 | 1995-09-12 | Item Development Aktiebolag | Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty |
DE3739650C1 (de) * | 1987-11-23 | 1989-05-24 | Immuno Ag | Fermenter zum Zuechten von Zellkulturen |
US5180366A (en) * | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
US5792325A (en) * | 1990-11-15 | 1998-08-11 | Richardson, Jr.; William H. | Electric arc material processing system |
US5293875A (en) * | 1992-06-16 | 1994-03-15 | Natus Medical Incorporated | In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods |
AU673057B2 (en) * | 1993-02-22 | 1996-10-24 | Abraxis Bioscience, Llc | Methods for (in vivo) delivery of biologics and compositionsuseful therefor |
US5763431A (en) * | 1993-08-20 | 1998-06-09 | Jackson; Meyer B. | Method for regulating neuropeptide hormone secretion |
DE4421433C1 (de) * | 1994-06-18 | 1995-06-08 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung |
US5476764A (en) * | 1994-09-16 | 1995-12-19 | The Regents Of The University Of California | Method using CO for extending the useful shelf-life of refrigerated red blood cells |
US6066333A (en) * | 1994-09-22 | 2000-05-23 | William Harvey Research Limited | Pharmaceutical control of inflammation |
US5664563A (en) * | 1994-12-09 | 1997-09-09 | Cardiopulmonary Corporation | Pneumatic system |
US5914316A (en) * | 1994-12-16 | 1999-06-22 | Washington University | Method of inhibiting intimal hyperplasia |
US5712293A (en) * | 1995-06-07 | 1998-01-27 | Sepracor, Inc. | Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride |
FR2735382B1 (fr) * | 1995-06-15 | 1997-07-25 | Air Liquide | Installation de production de monoxyde de carbone incorporant une unite de separation cryogenique |
ES2217313T3 (es) * | 1995-06-30 | 2004-11-01 | Zymogenetics, Inc. | Bencenosulfonamidas o sulfonilureas de 4-(2-(n-(-2-carboxamidoindol)aminoetilo) como antagonistas del pdfg. |
JP2000510448A (ja) * | 1996-04-05 | 2000-08-15 | ザ ジェネラル ホスピタル コーポレーション | 異常ヘモグロビン症の治療 |
US6069132A (en) * | 1996-08-14 | 2000-05-30 | Revanker; Ganapathi R. | Phosphazole compounds |
US8128963B2 (en) * | 1996-09-27 | 2012-03-06 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
US6316403B1 (en) * | 1996-09-27 | 2001-11-13 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
DE69925819T2 (de) * | 1998-03-16 | 2006-05-18 | Celgene Corp. | 2-(2,6-dioxopiperidin-3-yl)isoindolin derivate, deren herstellung und deren verwendung als inhibitoren von entzündungszytokinen |
US6203991B1 (en) * | 1998-08-21 | 2001-03-20 | The Regents Of The University Of Michigan | Inhibition of smooth muscle cell migration by heme oxygenase I |
US7678390B2 (en) * | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
US20050250688A1 (en) * | 1999-04-01 | 2005-11-10 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
US7632803B2 (en) * | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
US20040197271A1 (en) * | 2001-03-20 | 2004-10-07 | Kunka Robert Leonard | Inhalation drug combinations |
IL158182A0 (en) * | 2001-03-30 | 2004-03-28 | Sangstat Medical Corp | Carbon monoxide generating compounds for treatment of vacular, inflammatory and immune disorders |
GB0111872D0 (en) * | 2001-05-15 | 2001-07-04 | Northwick Park Inst For Medica | Therapeutic agents and methods |
US7122027B2 (en) * | 2001-05-25 | 2006-10-17 | Medtronic, Inc. | Implantable medical device with controllable gaseous agent release system |
WO2003000114A2 (en) * | 2001-06-21 | 2003-01-03 | Beth Israel Deaconess Medical Center | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis |
US7069026B2 (en) * | 2001-06-28 | 2006-06-27 | Nokia Corporation | Geographic area assisted system selection for mobile stations |
CA2475209A1 (en) * | 2002-02-04 | 2003-08-14 | Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda. | Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
BRPI0307673A2 (pt) * | 2002-02-13 | 2016-11-08 | Beth Israel Hospital | métodos de tratar doença vascular. |
UA86570C2 (ru) * | 2002-04-15 | 2009-05-12 | Юниверсити Оф Питтсбург Оф Дзе Коммонвелз Систем Оф Хайер Эдьюкейшн | Способ лечения некротизирующего энтероколита |
MXPA04010243A (es) * | 2002-04-15 | 2005-07-05 | Univ Pittsburgh | Metodos para tratar ileo. |
US20040052866A1 (en) * | 2002-05-17 | 2004-03-18 | Otterbein Leo E. | Methods of treating hepatitis |
AU2003279236B8 (en) * | 2002-06-21 | 2009-02-19 | Beth Israel Deaconess Medical Center, Inc. | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
EA200500782A1 (ru) * | 2002-11-07 | 2005-10-27 | Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн | Лечение геморрагического шока |
-
2003
- 2003-06-05 CA CA002487413A patent/CA2487413A1/en not_active Abandoned
- 2003-06-05 RS YUP-1053/04A patent/RS105304A/sr unknown
- 2003-06-05 UA UAA200500061A patent/UA87438C2/ru unknown
- 2003-06-05 PL PL03374375A patent/PL374375A1/xx not_active Application Discontinuation
- 2003-06-05 JP JP2004510706A patent/JP2005532351A/ja active Pending
- 2003-06-05 AU AU2003248621A patent/AU2003248621A1/en not_active Abandoned
- 2003-06-05 EP EP03757348A patent/EP1509237A4/en not_active Withdrawn
- 2003-06-05 US US10/455,564 patent/US20040258772A1/en not_active Abandoned
- 2003-06-05 MX MXPA04012167A patent/MXPA04012167A/es not_active Application Discontinuation
- 2003-06-05 WO PCT/US2003/017731 patent/WO2003103585A2/en active Application Filing
- 2003-06-05 CN CNA038188724A patent/CN1674922A/zh active Pending
- 2003-06-05 EA EA200401622A patent/EA200401622A1/ru unknown
-
2004
- 2004-12-01 HR HR20041146A patent/HRP20041146A2/xx not_active Application Discontinuation
- 2004-12-07 NO NO20045354A patent/NO20045354L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PL374375A1 (en) | 2005-10-17 |
US20040258772A1 (en) | 2004-12-23 |
CA2487413A1 (en) | 2003-12-18 |
JP2005532351A (ja) | 2005-10-27 |
EP1509237A4 (en) | 2006-07-12 |
EP1509237A2 (en) | 2005-03-02 |
WO2003103585A3 (en) | 2004-08-26 |
MXPA04012167A (es) | 2005-09-21 |
NO20045354L (no) | 2004-12-22 |
AU2003248621A1 (en) | 2003-12-22 |
WO2003103585A2 (en) | 2003-12-18 |
UA87438C2 (ru) | 2009-07-27 |
HRP20041146A2 (en) | 2005-06-30 |
CN1674922A (zh) | 2005-09-28 |
EA200401622A1 (ru) | 2005-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003103585A3 (en) | METHODS OF TREATING ANGIOGENESIS, TUMOR GROWTH AND METASTASES | |
HRP20041071A2 (en) | Methods of treating hepatitis | |
RS91004A (en) | Methods of treating ileus | |
IL280818A (en) | Methods of production of alpha-galactosides preparations | |
MX349188B (es) | Sns - 595 y metodos para utilizar el mismo. | |
HK1217103A1 (zh) | 二芳基乙內酰脲化合物 | |
RS91104A (en) | Methods of treating necrotizing enterocolitis | |
HK1120427A1 (en) | Anti-glypican-3 antibody | |
RS20050344A (en) | Treatment for hemorrhagic shock | |
MY150237A (en) | Cripto blocking antibodies and uses thereof | |
CA2301032A1 (en) | A method of preventing or treating estrogen-dependent diseases and disorders | |
UA72927C2 (uk) | Композиція для лікування печінково-клітинного раку, що містить доцетаксель | |
WO2004073615A3 (en) | Deazaflavin compounds and methods of use thereof | |
AU2003229876A1 (en) | Tumour associated antigens | |
TW200509925A (en) | Method comprising irinotecan for treatment of breast cancer | |
TW200626150A (en) | Use of Epothilones in the treatment of bone metastasis | |
DE60335535D1 (de) | Zusammensetzung und verfahren zur abtötung von tumoren | |
WO2003006657A3 (de) | Genregulatorische elemente zur gentherapie, zur prävention und diagnose von metastasen und zur gentherapie von tumoren | |
TW200614997A (en) | Leaf juice of plectranthus amboinicus for treating cancer and/or tumor | |
UA67076A (en) | Method for treating locally disseminated cancer of larynx located in supraglottis and glottis | |
MXPA02001238A (es) | Uso de la hidralazina y procanaimida en el tratamiento de cancer como reactivadores de la expresion de genes supresores de tumores. |